0.9397
price down icon3.12%   -0.0303
 
loading
Schlusskurs vom Vortag:
$0.97
Offen:
$0.97
24-Stunden-Volumen:
128.06K
Relative Volume:
0.59
Marktkapitalisierung:
$16.36M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-52.53M
KGV:
-0.2567
EPS:
-3.66
Netto-Cashflow:
$-39.93M
1W Leistung:
-3.12%
1M Leistung:
-48.51%
6M Leistung:
-32.88%
1J Leistung:
-37.35%
1-Tages-Spanne:
Value
$0.9102
$0.97
1-Wochen-Bereich:
Value
$0.9102
$1.03
52-Wochen-Spanne:
Value
$0.8531
$3.10

Unity Biotechnology Inc Stock (UBX) Company Profile

Name
Firmenname
Unity Biotechnology Inc
Name
Telefon
(650) 416-1192
Name
Adresse
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Name
Mitarbeiter
16
Name
Twitter
@unitybiotech
Name
Nächster Verdiensttermin
2024-11-11
Name
Neueste SEC-Einreichungen
Name
UBX's Discussions on Twitter

Vergleichen Sie UBX mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
UBX
Unity Biotechnology Inc
0.9397 16.36M 0 -52.53M -39.93M -3.66
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
477.52 127.47B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
561.49 62.43B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
595.70 37.03B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
232.75 31.06B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
229.22 26.16B 3.81B -644.79M -669.77M -6.24

Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-08-22 Eingeleitet Rodman & Renshaw Buy
2023-11-16 Hochstufung Wedbush Neutral → Outperform
2022-01-04 Hochstufung ROTH Capital Neutral → Buy
2021-11-10 Hochstufung Mizuho Neutral → Buy
2021-06-28 Hochstufung Citigroup Sell → Buy
2021-06-07 Eingeleitet H.C. Wainwright Buy
2021-02-16 Herabstufung Citigroup Neutral → Sell
2020-08-18 Herabstufung Citigroup Buy → Neutral
2020-08-18 Herabstufung Mizuho Buy → Neutral
2020-08-18 Herabstufung Morgan Stanley Overweight → Equal-Weight
2020-08-17 Herabstufung ROTH Capital Buy → Neutral
2020-07-28 Eingeleitet ROTH Capital Buy
2019-12-12 Eingeleitet Cantor Fitzgerald Overweight
2019-03-07 Eingeleitet Cantor Fitzgerald Overweight
2018-09-07 Eingeleitet Mizuho Buy
2018-05-29 Eingeleitet Citigroup Buy
2018-05-29 Eingeleitet Goldman Neutral
2018-05-29 Eingeleitet Morgan Stanley Overweight
Alle ansehen

Unity Biotechnology Inc Aktie (UBX) Neueste Nachrichten

pulisher
Apr 05, 2025

Unity Biotechnology stock hits 52-week low at $0.94 By Investing.com - Investing.com Canada

Apr 05, 2025
pulisher
Apr 04, 2025

Unity Biotechnology stock hits 52-week low at $0.94 - Investing.com

Apr 04, 2025
pulisher
Apr 03, 2025

Unity Biotechnology CFO Lynne Sullivan sells $22,523 in stock By Investing.com - Investing.com Australia

Apr 03, 2025
pulisher
Apr 03, 2025

Unity Biotechnology CFO Lynne Sullivan sells $22,523 in stock - Investing.com

Apr 03, 2025
pulisher
Apr 03, 2025

Unity Biotechnology Executives Sell Shares for Tax Obligations - TradingView

Apr 03, 2025
pulisher
Mar 29, 2025

HC Wainwright Has Pessimistic Outlook of UBX FY2026 Earnings - The AM Reporter

Mar 29, 2025
pulisher
Mar 28, 2025

What is HC Wainwright’s Estimate for UBX FY2026 Earnings? - Defense World

Mar 28, 2025
pulisher
Mar 26, 2025

Unity Biotechnology (NASDAQ:UBX) Price Target Lowered to $4.00 at Chardan Capital - Defense World

Mar 26, 2025
pulisher
Mar 25, 2025

H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

UBX Stock Down 29% on Mixed Results From Phase II Eye Disease Study - MSN

Mar 25, 2025
pulisher
Mar 25, 2025

Unity Biotechnology price target lowered to $4 from $6 at Chardan - TipRanks

Mar 25, 2025
pulisher
Mar 25, 2025

H.C. Wainwright cuts Unity Biotechnology target to $4; keeps buy rating By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

UNITY Biotechnology tanks on mixed results for eye disease drug - The Pharma Letter

Mar 25, 2025
pulisher
Mar 25, 2025

Mizuho maintains Unity Biotechnology Outperform rating By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 25, 2025

Chardan Cuts Price Target on Unity Biotechnology to $4 From $6, Keeps Buy Rating - Marketscreener.com

Mar 25, 2025
pulisher
Mar 25, 2025

Mizuho maintains Unity Biotechnology Outperform rating - Investing.com India

Mar 25, 2025
pulisher
Mar 25, 2025

Unity Biotechnology (NASDAQ:UBX) Price Target Cut to $4.00 by Analysts at HC Wainwright - Defense World

Mar 25, 2025
pulisher
Mar 24, 2025

UNITY Biotechnology to Host Virtual Investor Event to Discuss 24- and 36-Week Data from the Phase 2b ASPIRE - EIN News

Mar 24, 2025
pulisher
Mar 24, 2025

Sector Update: Health Care Stocks Rise Late Afternoon - TradingView

Mar 24, 2025
pulisher
Mar 24, 2025

Sector Update: Health Care - TradingView

Mar 24, 2025
pulisher
Mar 24, 2025

Unity Biotechnology Shares Decline After Diabetic Edema Treatment Misses Primary Endpoint - Marketscreener.com

Mar 24, 2025
pulisher
Mar 24, 2025

UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial - MSN

Mar 24, 2025
pulisher
Mar 24, 2025

HC Wainwright Adjusts Unity Biotechnology Price Target to $4 From $8, Maintains Buy Rating - Marketscreener.com

Mar 24, 2025
pulisher
Mar 24, 2025

UNITY Biotechnology Shares Drop 33% After Phase 2b Trial Data on UBX1325 in Diabetic Macular Edema - Yahoo

Mar 24, 2025
pulisher
Mar 24, 2025

Unity Biotechnology Unveils Mixed Data From Study For Diabetes-Related Blindness, Stock Falls - Benzinga

Mar 24, 2025
pulisher
Mar 24, 2025

Unity Biotechnology, Inc. Announces Topline Results from the ASPIRE Phase 2B Study in Diabetic Macular Edema - MarketScreener

Mar 24, 2025
pulisher
Mar 24, 2025

UNITY Biotechnology Announces Topline Results from the ASPIRE Phase 2b Study in Diabetic Macular Edema - GlobeNewswire

Mar 24, 2025
pulisher
Mar 24, 2025

New DME Treatment Matches Standard Care: Phase 2b Shows Promising Vision Gains - Stock Titan

Mar 24, 2025
pulisher
Mar 23, 2025

China’s Plans for a $900 Billion Space Project, but Can It Catch Up to SpaceX? - The Globe and Mail

Mar 23, 2025
pulisher
Mar 23, 2025

UNITY Biotechnology's UBX1325: A Game Changer for DME Treatment? - AInvest

Mar 23, 2025
pulisher
Mar 23, 2025

UNITY Biotechnology to Host Virtual Investor Event Featuring Phase 2b ASPIRE Study Results for UBX1325 in Diabetic Macular Edema - Nasdaq

Mar 23, 2025
pulisher
Mar 23, 2025

UNITY Biotechnology to Host Virtual Investor Event to - GlobeNewswire

Mar 23, 2025
pulisher
Mar 23, 2025

Key Phase 2b Data Coming: UNITY's DME Treatment Could Transform Eye Disease Care - Stock Titan

Mar 23, 2025
pulisher
Mar 22, 2025

Where Will QuantumScape Stock Be in 3 Years? - The Globe and Mail

Mar 22, 2025
pulisher
Mar 20, 2025

This Micro Cap Continues This Week's Dominance Amid New CEO Appointment - The Globe and Mail

Mar 20, 2025
pulisher
Mar 20, 2025

RECONAFRICA ANNOUNCES ACCELERATION OF DRILLING INTO Q2 2025 AND A CORPORATE UPDATE - The Globe and Mail

Mar 20, 2025
pulisher
Mar 19, 2025

3 Reasons to Avoid AIR and 1 Stock to Buy Instead - The Globe and Mail

Mar 19, 2025
pulisher
Mar 17, 2025

This Media Stock Is Finding Serious Success Prior To Opening Bell - The Globe and Mail

Mar 17, 2025
pulisher
Mar 16, 2025

Unity Biotechnology Reports 2024 Financial Results and Updates - MSN

Mar 16, 2025
pulisher
Mar 15, 2025

Unity Biotechnology announces upcoming trial data and new board of directors member - Ophthalmology Times

Mar 15, 2025
pulisher
Mar 14, 2025

Chardan Capital Has Bullish Outlook for UBX FY2025 Earnings - Defense World

Mar 14, 2025
pulisher
Mar 13, 2025

HC Wainwright Has Strong Estimate for UBX FY2025 Earnings - Defense World

Mar 13, 2025
pulisher
Mar 12, 2025

Analysts Issue Forecasts for UBX Q1 Earnings - Defense World

Mar 12, 2025
pulisher
Mar 11, 2025

Unity Biotechnology (NASDAQ:UBX) Receives “Buy” Rating from Chardan Capital - Defense World

Mar 11, 2025
pulisher
Mar 10, 2025

UNITY Biotechnology appoints Yehia Hashad to its board -March 10, 2025 at 10:40 am EDT - Marketscreener.com

Mar 10, 2025

Finanzdaten der Unity Biotechnology Inc-Aktie (UBX)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$20.07
price up icon 0.15%
$69.51
price down icon 4.32%
$32.19
price down icon 1.26%
$25.22
price up icon 2.48%
$101.81
price up icon 3.09%
biotechnology ONC
$229.22
price down icon 0.76%
Kapitalisierung:     |  Volumen (24h):